Traders Purchase Large Volume of Put Options on Evelo Biosciences (NASDAQ:EVLO)

Evelo Biosciences, Inc. (NASDAQ:EVLO) was the recipient of some unusual options trading on Wednesday. Investors acquired 1,885 put options on the company. This represents an increase of 1,101% compared to the average volume of 157 put options.

Institutional Trading of Evelo Biosciences

Large investors have recently made changes to their positions in the business. FMR LLC grew its holdings in shares of Evelo Biosciences by 1,835.1% during the third quarter. FMR LLC now owns 2,446,390 shares of the company’s stock worth $9,590,000 after purchasing an additional 2,319,965 shares during the last quarter. Susquehanna International Group LLP boosted its holdings in Evelo Biosciences by 549.9% in the fourth quarter. Susquehanna International Group LLP now owns 146,059 shares of the company’s stock valued at $235,000 after acquiring an additional 123,586 shares during the last quarter. Trustees of Columbia University in the City of New York bought a new position in Evelo Biosciences in the fourth quarter valued at about $183,000. Citigroup Inc. boosted its holdings in Evelo Biosciences by 1,522.6% in the fourth quarter. Citigroup Inc. now owns 99,625 shares of the company’s stock valued at $160,000 after acquiring an additional 93,485 shares during the last quarter. Finally, Morgan Stanley boosted its holdings in Evelo Biosciences by 22.6% in the fourth quarter. Morgan Stanley now owns 78,892 shares of the company’s stock valued at $127,000 after acquiring an additional 14,567 shares during the last quarter. Institutional investors own 0.31% of the company’s stock.

Evelo Biosciences Price Performance

Shares of NASDAQ:EVLO opened at $0.05 on Friday. The business’s fifty day moving average price is $0.05 and its two-hundred day moving average price is $0.42. Evelo Biosciences has a fifty-two week low of $0.03 and a fifty-two week high of $13.93. The stock has a market capitalization of $949,000.00, a price-to-earnings ratio of 0.00 and a beta of 2.03.

About Evelo Biosciences

Evelo Biosciences, Inc, a clinical-stage biotechnology company, focuses on discovering and developing oral medicines that act on immune cells in the small intestine with systemic effects. It is developing EDP1815, a whole-microbe product candidate, which has completed a Phase 2 trial for the treatment of psoriais; and is in Phase 2 clinical trial for the treatment of atopic dermatitis.